Nice post and update from Phred could refresh our sticky's

New Post Public Reply Private Reply Replies (0) Message Board
12 year pipedream
Nice post and update from Phred could refresh our sticky's here

PPS $EWSI is still massively undervalued.

I don't feel the need to post very often, unless I see something that needs clarity, but we’re due for a re-write on how EWSI trades vs. other OTC stocks, as well as take look at some 2014 projections. If you are investing, you should learn all you can about the company and read the EDGAR/SEC filings rather than rely on the opinions of those on a message board, my opinion included.

Information is KING in my book. I have done some simple due diligence by pulling out numbers from all financials and making some mathematical implications. Real Information.

Those that believed in Martie knew the numbers would be audited, and will continue to be audited, and they will come out on time. Nobody liked seeing the Chinese revenue peeled back, and we can only rely on past statements from Martie on guidance. I’m hoping the new relationship with RSBM, LLP is the correct firm with the correct accounting expertise in this area of Chinese leasing. Time will tell.

Read all the K's, and all the statements from the CEO. Some like to bash the accountant, or the change of accountants or something of the like, but the reality is that this is a real company and they are filing numbers through the SEC in a timely manner.

The open letter & 8K states that they are, indeed, trying to solve the international PCAOB issue and get the fruit of their labor on the books. Hopefully they can solve the problem quickly and move forward. I, like several other investors on here would like to see a few audited Quarters. There is no rule against this and it would do a great deal to restore some instant faith in both Management and the business plan.

I keep thinking this stock should shake loose of all the games and start to actually trade logically. I guess putting logic out instead of fear and disinformation might be helpful to potential investors.

I've been to EWSI facilities and attended the grand opening in Cincinnati. I know Martie. Martie is ALL about measurables. There are those that like to give him a daily bash, but he is a good guy, and he has yet to sell any shares.

You can feel free to look it up at EDGAR. All verifiable. In fact NO insider has sold yet.

Again, I did not like the revolving accountant game last year. It made everyone uneasy and did nothing but fuel rampant speculation. Time will tell if Martie corrected the deficiency, and that he finally found the right accounting firm with the right area of expertise.

Give Martie his props here. He had to eat a boatload of crow based on prior projections. As a businessman, I’m sure it killed him to have to leave that revenue on the table. If the 10K had come out with $18M on it audited, less people would have questioned his competence. Dealing with adversity in growth is also a solid character trait. Investor confidence is horribly shaken, however and he has to deliver on revenue and solve the Chinese PCAOB issue. Don’t tell me about the pain anymore – show me the baby.

Again, an audited Q would be very beneficial. Swallowing the pain and getting the correct accountant as early as possible in the business may end up being good foresight as China is expanding fast, and it appears all the major accounting companies are challenged in the nuances of Chinese accounting. From a revenue perspective it is the lion’s share of the current business, and the controls and systems need to be built to be easily auditable.


Its time to again revisit basic math on $EWSI. The longs know what they hold, and here's why we toss out the emotional games and look at the numbers.

Based on 345-400M shares.

Martie said that 2013 would be substantially ahead of $12M. We still have no idea what substantially means, but lets just pick a number. I originally was running with $19M based on Sadler statements, as well as the 2Q & 3Q unaudited numbers that CLEARLY CONTAINED THE CHINESE REVENUE EXPECTATIONS. Hate it or not, I’m not willing to call Martie a liar, just because of PCAOB problems. Lets just say $18M for a nice pretty number.

Awesome growth, and Martie has stated that he will continue to focus on his growth as a priority for 2014. Feel free to scale the Q4 up and down based on your own DD.

The next thing we have to discuss is a multiplier value. I’ve used all sorts of econometric modeling to test out different theories, but a good back of the envelope Market Cap multiplier should be about 5+ times a company's annual revenue. This multiplier adjusts up or down for profitability, growth, assets and other variables, but it is a good back of the envelope estimator. Feel free to use your own. I modeled everything from 2.25 to 7.75.

$18MM, making market cap 5x18=$90 Market Cap
@ 345,000,000 = $0.26 PPS

Today we closed at $0.0219 with a Market Cap of 5.8M. So right now we not only have a PPS BELOW the annualize revenue, but we are trading substantially below a completely reasonable PPS estimate.

Lets roll into 2014 Numbers, and use Martie’s words on projections, but doubling of Q’s has to slow down at some point. You can play with this as well, but thus far, one must take Martie at his word on his business plan for 2014. I’m going to take his $50M estimate and over perform to $60M. He likes to downplay numbers so he can surprise in a positive way.

At this point we should talk dilution and move the O/S to 400M. You can play with this number as well. As long as growth continues, I’m comfortable with controlled dilution. I’m tired of the dilution that went on 1Q. So tired of it, and it has to stop for a while to help out the retail investors.

Hopefully any future S8 shares will be tied to performance benchmarks, especially for consultants. Tie them up for a year as well. Lots of flippers get hung up on dilution, and there's been a huge amount speculated on this, but proper dilution does have its place in growing a company out. These are my estimates and you can scale them at will.

Q4 -13 ~10M

Q1 -14 ~12M
Q2 -14 ~15M
Q3 -14 ~15M
Q4 -14 ~18M
2014 TOTAL: $60M

Market cap: depends on multiplier.
At 3.0 = $180M or $0.45 PPS @ 400M Shares
At 5.0 = $300M or $0.75 PPS @ 400M Shares

Feel free to mod the math with your own projections. Do your own DD on this one. It is one of the only OTC stocks that I trade, as it operates with the clarity and filing of a big board company.

A Theory on uplisting. The clear issue is PPS qualifications. A reverse split would get it there, as long as the revenue issues are solved and the market corrects. I’d be all for it if it was trading at $.75 and they needed it at $1.50 or $2.00 That makes sense. My theory expands on that. What about an acquisition of an existing weak company on a better exchange. I’d personally put logistics companies into play, as well as any company with good I/E capabilities. This is just a theory. It really needs to be fleshed out, but why not?

E-Waste Systems, Inc. (EWSI) Stock Research Links

EWSI Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

U.S. Green Beret's Mission: Clearing Landmines in Ukraine

Updated Category News Views 1

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 4

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 4

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 6

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 9

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 9

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 2

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 2

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 5

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
USPS Honors 150 Years of the U.S. Coast Guard Academy

Updated Category News Views 6

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Continue Reading

Top 5 Most Recently Viewed Articles

Cingulate Inc. Shows Progress with Q2 2025 Financial Results

Updated Category News Views 142

Cingulate Inc. Announced Financial Highlights for Q2 2025 Cingulate Inc. (NASDAQ: CING), a prominent biopharmaceutical company focused on innovative ADHD treatments, recently disclosed its financial results for the second quarter of 2025, alongside significant advancements. Central to the company’s activities was the submission of the New Drug Application (NDA) for its...

Continue Reading
Discover How Your Investment in Carvana Could Have Grown

Updated Category News Views 127

Investment Growth Over Five Years Investing wisely can create remarkable returns over time. A case in point is Carvana Co (NASDAQ: CVNA), which has significantly outperformed expectations in recent years. Over the past five years, Carvana has shown an impressive annualized return of 18.46%, surpassing the market by 4.39% each year. Presently, Carvana's market...

Continue Reading
Deko Cocktails Triumphs with Best New RTD Award Success

Updated Category News Views 92

Deko Cocktails Achieves WSWA Best RTD Award Deko Cocktails, a newly launched line of expertly crafted ready-to-serve cocktails, recently secured a prestigious accolade in the beverage alcohol industry. The company was honored with the Best RTD (Ready to Drink) Product of the Year at the Wine & Spirit Wholesalers of America (WSWA) Brand Battle. This annual competition...

Continue Reading
Bouygues SA Shares and Voting Rights Update for January 2025

Updated Category News Views 205

Key Insights on Bouygues SA's Monthly Share and Voting Rights Bouygues SA regularly updates its shareholders about essential metrics, including the total number of shares and the voting rights attached to them. Understanding these details is vital for investors and stakeholders who wish to stay informed of the company's standing in the market. Transparency in Shareholder...

Continue Reading
Challenges Faced by Oncternal Therapeutics and Stock Update

Updated Category News Views 94

Oncternal Therapeutics Inc. (ONCT) was in dire straits back then, hitting a notable low of $1.31 amidst a turbulent market that left investors biting their nails. This stock plunge represented a hefty drop of -76.33%, rattling traders who were already on edge over the biopharmaceutical company’s struggle to bring innovative cancer therapies to market. The company's...

Continue Reading